Purpose: Genomic instability is a hallmark of cancer and target-ing DNA damage response (DDR) is emerging as a promising therapeutic strategy in different solid tumors. The effectiveness of targeting DDR in colorectal cancer has not been extensively explored. Experimental Design: We challenged 112 cell models recapit-ulating the genomic landscape of metastatic colorectal cancer with ATM, ATR, CHK1, WEE1, and DNA-PK inhibitors, in parallel with chemotherapeutic agents. We focused then on ATR inhibitors (ATRi) and, to identify putative biomarkers of response and resistance, we analyzed at multiple levels colorectal cancer models highly sensitive or resistant to these drugs. Results: We found that around 30% of colorectal cancers, including those carrying KRAS and BRAF mutations and unre-sponsive to targeted agents, are sensitive to at least one DDR inhibitor. By investigating potential biomarkers of response to ATRi, we found that ATRi-sensitive cells displayed reduced phos-pho-RPA32 foci at basal level, while ATRi-resistant cells showed increased RAD51 foci formation in response to replication stress. Lack of ATM and RAD51C expression was associated with ATRi sensitivity. Analysis of mutational signatures and HRDetect score identified a subgroup of ATRi-sensitive models. Organoids derived from patients with metastatic colorectal cancer recapitulated find-ings obtained in cell lines. Conclusions: In conclusion, a subset of colorectal cancers refrac-tory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer / E. Durinikova, N.M. Reilly, K. Buzo, E. Mariella, R. Chilà, A. Lorenzato, J.M.L. Dias, G. Grasso, F. Pisati, S. Lamba, G. Corti, A. Degasperi, C. Cancelliere, G. Mauri, P. Andrei, M. Linnebacher, S. Marsoni, S. Siena, A. Sartore-Bianchi, S. Nik-Zainal, F. Di Nicolantonio, A. Bardelli, S. Arena. - In: CLINICAL CANCER RESEARCH. - ISSN 1078-0432. - 28:17(2022 Sep 01), pp. 3874-3889. [10.1158/1078-0432.CCR-22-0875]

Targeting the DNA Damage Response Pathways and Replication Stress in Colorectal Cancer

F. Pisati;G. Mauri;S. Siena;A. Sartore-Bianchi;
2022

Abstract

Purpose: Genomic instability is a hallmark of cancer and target-ing DNA damage response (DDR) is emerging as a promising therapeutic strategy in different solid tumors. The effectiveness of targeting DDR in colorectal cancer has not been extensively explored. Experimental Design: We challenged 112 cell models recapit-ulating the genomic landscape of metastatic colorectal cancer with ATM, ATR, CHK1, WEE1, and DNA-PK inhibitors, in parallel with chemotherapeutic agents. We focused then on ATR inhibitors (ATRi) and, to identify putative biomarkers of response and resistance, we analyzed at multiple levels colorectal cancer models highly sensitive or resistant to these drugs. Results: We found that around 30% of colorectal cancers, including those carrying KRAS and BRAF mutations and unre-sponsive to targeted agents, are sensitive to at least one DDR inhibitor. By investigating potential biomarkers of response to ATRi, we found that ATRi-sensitive cells displayed reduced phos-pho-RPA32 foci at basal level, while ATRi-resistant cells showed increased RAD51 foci formation in response to replication stress. Lack of ATM and RAD51C expression was associated with ATRi sensitivity. Analysis of mutational signatures and HRDetect score identified a subgroup of ATRi-sensitive models. Organoids derived from patients with metastatic colorectal cancer recapitulated find-ings obtained in cell lines. Conclusions: In conclusion, a subset of colorectal cancers refrac-tory to current therapies could benefit from inhibitors of DDR pathways and replication stress. A composite biomarker involving phospho-RPA32 and RAD51 foci, lack of ATM and RAD51C expression, as well as analysis of mutational signatures could be used to identify colorectal cancers likely to respond to ATRi.
Settore MED/06 - Oncologia Medica
26-lug-2022
Article (author)
File in questo prodotto:
File Dimensione Formato  
3874.pdf

accesso aperto

Tipologia: Publisher's version/PDF
Dimensione 2.3 MB
Formato Adobe PDF
2.3 MB Adobe PDF Visualizza/Apri
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/935347
Citazioni
  • ???jsp.display-item.citation.pmc??? 1
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 1
social impact